Akums Drugs IPO Oversubscribed 4.4 Times on Day 2
Jul 31, 2024 20:51
Akums Drugs and Pharmaceuticals IPO receives 4.43 times subscription on Day 2, with strong interest from retail and institutional investors. The issue closes on Thursday.
New Delhi, Jul 31 (PTI) The initial public offer of Akums Drugs and Pharmaceuticals received 4.43 times subscription on the second day of subscription on Wednesday.
The Rs 1,875-crore initial share sale received bids for 6,71,69,960 shares, as against 1,51,62,239 shares on offer, translating to 4.43 times subscription, as per the NSE data.
The issue will conclude on Thursday.
The quota for Retail Individual Investors (RIIs) received 8.98 times subscription, while the Non Institutional Investors part got subscribed 8.48 times. The portion for Qualified Institutional Buyers (QIBs) received 96 per cent subscription.
The IPO is a combination of a fresh issue of equity shares worth Rs 680 crore and an offer-for-sale (OFS) of 1.73 crore shares valued at Rs 1,177 crore at the upper-end of the price band by promoters and an existing investor.
Those selling shares in the OFS are Sanjeev Jain, Sandeep Jain and Ruby QC Investment Holdings Pte Ltd.
The public issue has a price range of Rs 646 to Rs 679 per share
Akums Drugs and Pharmaceuticals Ltd on Monday said it has collected Rs 829 crore from anchor investors.
Proceeds from the fresh issue will be used to repay debt, fund working capital requirements of the company, pursue inorganic growth initiatives through acquisition, and for general corporate purposes.
Brokerage houses have pegged the company's market capitalisation at Rs 10,697 crore post-issue.
Founded in 2004, Akums is a pharmaceutical contract development and manufacturing organization (CDMO), offering a comprehensive range of pharmaceutical products and services in India and overseas.
As of September 30, 2023, key clients for the company's CDMO business include Alembic Pharmaceuticals, Alkem Laboratories, Cipla, Dabur India, Dr Reddy's Laboratories, Hetero Healthcare, Ipca Laboratories, Mankind Pharma, MedPlus Health Services, Micro Labs, Mylan Pharmaceuticals, Natco Pharma, Sun Pharmaceutical Industries, and Amishi Consumer Technologies (The Mom's Co).
ICICI Securities, Axis Capital, Citigroup Global Markets India and Ambit Pvt Ltd are the running lead managers to the issue.
The equity shares of the company are proposed to be listed on BSE and NSE.
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.